SB939 reduces the viability of primary CML progenitors with the <i>BIM</i> deletion polymorphism.

<p>Results of apoptotic cell death, as assessed by flow cytometry-based Annexin V assay, for primary CML cells (A) without (n = 3) and (C) with (n = 2) the <i>BIM</i> deletion polymorphism are shown. Results of the colony formation assay for primary CML cells (B) without (n = 3) and (D) with (n = 4) the <i>BIM</i> deletion polymorphism are shown. Colony formation for each sample was calculated as a percentage of the total number of colonies counted from the corresponding DMSO-treated control. The P values were based on Student’s <i>t</i> test. ⁺P = 0.033, *P = 10⁻⁴ and ^#P = 2.8 X 10⁻⁴ in (B), *P = 0.0075 and ^#P = 10⁻⁶ in (D) were calculated by comparing their respective colony formation to that of the DMSO controls. ⁺⁺P = 0.0023, ^P = 0.0025, **P = 0.0071 and ^##P = 0.0025 in (B), ⁺P = 0.038, ^P = 0.021, **P = 0.019 and ^##P = 0.017 in (D) were calculated by comparing their respective colony formation to that of the sample treated with IM only. Cells were treated with either or both SB939 (0-1000nM) and imatinib (2uM) for 72 hours. All results are given as the mean ± s.e.m.